We anticipate that continued characterization of ex19del structures through experimental structural biology, additional detailed kinetics studies, and receptor signaling/crosstalk studies will be an important next step in ongoing efforts to design new treatment strategies for patients with EGFR-mutant NSCLC. Here, EGFR is linked to non-small cell lung carcinoma.